Goldman Sachs maintained a Neutral rating on Biogen (NASDAQ: BIIB) with a modified price target of $304.00 (from $283.00). Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE